14
Participants
Start Date
October 31, 2008
Primary Completion Date
March 31, 2011
Study Completion Date
July 31, 2011
eculizumab
eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
Placebo
Placebo IV weekly for 4 doses then every two weeks for 7 doses
Johns Hopkins University School of Medicine, Baltimore
Duke University Medical Center, Durham
Emory University, Atlanta
University of Florida & Shands Neuroscience Institute, Jacksonville
University of Alabama at Birmingham, Birmingham
Vanderbilt University Medical Center, Nashville
The Ohio State University, Columbus
Wishard Hospital, Indianapolis
Wayne State University, Detroit
University of Kansas Medical Center, Kansas City
University of Texas Southwestern Medical School, Dallas
University of California, Irvine, Orange
University of California - Davis, Sacramento
Massachusetts General Hospital, Boston
Caritas St. Elizabeths' Medical Center, Boston
Mount Sinai School of Medicine, New York
University of North Carolina at Chapel Hill, Chapel Hill
University Hospitals - Case Medical Center, Cleveland
The Warren Alpert Medical School of Brown University, Providence
The University of Vermont College of Medicine, Burlington
University of Virginia, Charlottesville
The Northern Alberta Clinical trials and Research Centre, Edmonton
Institute of Neurological Sciences, Department of Neurology, Southern General Hospital,, Glasgow
Institute of Neurology, London
Department of Clinical Neurology, West Wing, John Radcliffe Hospital, Oxford
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY